VANCOUVER and SYDNEY, New South Wales, Feb. 20, 2018 /CNW/ - PUF Ventures Inc. ("PUF" or the "Company") (CSE: PUF) (Frankfurt: PU3) (OTCPK: PUFXF), an advanced Access to Cannabis for Medical Purposes Regulations ("ACMPR") license applicant, and its strategic partner MYM Nutraceuticals (CSE: MYM) are pleased to announce a joint venture agreement between Southern Cross University and Solaris Nutraceuticals to commit to the development of hemp and medicinal cannabis products in the NSW Northern Rivers region that will enhance animal and human health. The agreement will pave the way for a flourishing industry built on the medicinal value of cannabis.
Vice-Chancellor Professor Adam Shoemaker said the agreement was a great step forward not just for the region, but also for consumers.
"Universities have a vital role to play as catalysts for diversification and development – creating new opportunities through 21st century industries," said Professor Shoemaker. "Legalized cannabis products are already playing a critically important role in delivering medicines, and through innovation, have the potential to improve the lives of millions more through new medical applications and nutrition. This agreement is a great example of Southern Cross University's commitment to engaging with industry and the community, so that we can create an environment for discovery and commercial development, driving changes in our back yard that can translate into benefits around the world."
Professor Shoemaker signed the agreement with Mr. Michael Horsfall, CEO of Solaris Nutraceuticals, committing to a new approach that brings together the University's internationally-recognized expertise in medicinal cannabis research with the corporate capabilities of Solaris Nutraceuticals.
The University's Lismore campus is equipped with high-security research laboratories where researchers work with the world's most diverse collection of cannabis seed and has already established an international reputation for botanical research. The decision of Solaris to establish a new medicinal cannabis plant in Casino, just a half hour drive from Lismore, has underscored the potential of this collaboration to yield substantial outcomes.
"This is an exciting opportunity not just for Solaris Nutraceuticals, but also for the Northern Rivers region," said Mr. Horsfall. "The project will deliver around 300 direct jobs and make a significant impact to the local economy and raise the socio-economic profile of the Northern Rivers region. On Friday, February 2, 2018, this project received grant funding of $2.5 million from the Australian Government as part of the Regional Jobs Investment Packages program (RJIP), a grant initiative that was made available by the Department of Industry, Innovation and Science. This is a significant step forward for our project and we are very appreciative of the support we have received from federal, state and local governments. Solaris Nutraceuticals will work with the University to identify opportunities to improve the properties and quality of medicines that can be derived from cannabis. These new collaborations hold tremendous potential and we are excited to be working towards a strong future together with Southern Cross."
About Southern Cross University
Australia's engaged university, Southern Cross, has maximized its impact by forging close partnerships with industry, communities and research partners around the world. With campuses in Lismore, Coffs Harbour and the Gold Coast, Southern Cross was founded in 1994 and is already ranked by Times Higher Education (THE) in the top 500 universities in the world, including ranking in the top 300 for life sciences.
About Solaris Nutraceuticals Inc.
Solaris Nutraceuticals is an innovative medical technology company headquartered in Sydney, Australia. The Company is owned by PUF Ventures Inc. (CSE: PUF), MYM Nutraceuticals Inc. (CSE: MYM), Chrome Holdings of Australia and private investors. It has submitted applications and plans with Australia's Office of Drug Control to build a 1.2 million square-foot greenhouse facility with cannabis production space and a medical research center in the Northern Rivers Region of New South Wales, Australia. Solaris' corporate mission is to deliver environmentally friendly, sun grown medicinal grade cannabis and to develop medicines and treatments for pain management and other medical conditions. The company's focus is on innovations that promote, support and deliver improvements in the quality, consistency and cost of medicines to our clients. For more information, visit www.solarisnutraceuticals.com.
About PUF Ventures Inc.
PUF Ventures Inc. is a growth oriented and diversified company focused on the international cannabis industry. It has ownership in several cannabis companies: AAA Heidelberg, Solaris Nutraceuticals Pty Ltd., and Natures Hemp Corp., and is actively pursuing other opportunities within the industry. PUF has an option to purchase 100% of AAA Heidelberg Inc., a private Ontario company and advanced applicant for an ACMPR license. Solaris Nutraceuticals is building the largest medical cannabis greenhouse in the Southern Hemisphere. For more information please visit: www.puf.ca.
ON BEHALF OF THE BOARD OF DIRECTORS
Derek Ivany President & CEO
No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of this release.
Some of the statements contained in this release are forward-looking statements, such as estimates and statements that describe the Issuer's future plans, objectives or goals, including words to the effect that the Issuer or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties.
SOURCE PUF Ventures
For further information: PUF Ventures Inc., E: [email protected], T: (800) 783-6056; Solaris Nutraceuticals, Michael Horsfall, President & CEO, E: [email protected], T: +61 417 041 272